Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Oculis Holding AGNASDAQ: OCS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of CHF 24.16M fell 76.7% year over year, behind the -32.9% change in trailing-twelve-month financing cash flow. Sequentially, it fell 70.8% from the prior quarter. Over 3 fiscal years it compounded at +370.6% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -76.7% toward the trailing-twelve-month pace of -32.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 24.16M-70.8% QoQ
Last fiscal yearDec 2025
CHF 178.6M+230.6% YoY
LTMMar 2026
CHF 105.86M-32.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.7%——
1 year+230.6%——
3-year CAGR+370.6%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CHF · from the cash flow

Latest · FY2025
178.6M CHF
Year-over-year change
+230.6%
4-year CAGR
+34.1%

Financing Cash Flow vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.9% is the 5th highest of 6, against a peer median of +23.2%.
  • Financing cash flow amounts to 21003.4% of revenue for OCS, versus a peer median of 1665.2%.
OCS Competitors
Financing Cash Flow for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$557.83M USD+3601.6%+628.3%1072.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$171.98M USD+5.5%—2258.5%
OCSOculis Holding AGLTM Mar 2026CHF 105.86M CHF-32.9%+370.6%21003.4%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$47.24M USD+93.8%-8.9%14179.4%
HROWHarrow Health, Inc.LTM Mar 2026$36.17M USD+23.2%—13.5%
OKYOOKYO Pharma LimitedFY2025$2.66M USD-57.2%+7.2%—
Peer median (excluding OCS) —+23.2%+7.2%1665.2%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.52M)(38.64M)(88.7M)(85.94M)(94.51M)
Depreciation & Amortization235K299K287K406K546K
Deferred Income Tax00000
Stock-Based Compensation328K804K3.61M9.78M16.04M
Change in Working Capital(791K)6M(12.99M)14.16M(70.67K)
Accounts Receivables233K(152K)36K247K1.9M
Inventory00000
Accounts Payables30K3.04M3.73M(1.71M)(1.86M)
Other Working Capital(1.05M)3.11M(16.76M)15.62M(106.97K)
Other Non-Cash Items4.93M6.47M43.95M14.09M15.77M
Operating Cash Flow(13.83M)(25.07M)(53.85M)(47.5M)(62.22M)
Capital Expenditures(28K)(3.55M)(48K)(230K)(287.47K)
Acquisitions (Net)00000
Purchases of Investments00(54.16M)(17.33M)(58.05M)
Sales of Investments00000
Other Investing Activities0(3.48M)000
Investing Cash Flow(28K)(3.55M)(54.21M)(17.56M)(59.38M)
Debt Repayment(98K)(159K)(158K)(274K)(373K)
Common Stock Issued00135.62M53.54M178.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(804K)(157K)(5.79M)763K16.77K
Financing Cash Flow55.19M1.71M129.67M54.03M178.6M
Effect of Forex Changes(16K)418K(3.08M)407K174.39K
Net Change in Cash41.33M(26.49M)18.54M(10.62M)57.17M
Free Cash Flow(13.85M)(28.62M)(53.89M)(47.73M)(62.51M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.